Shares of Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$1.02 and last traded at C$1.16, with a volume of 19624 shares traded. The stock had previously closed at C$1.79.
Wall Street Analyst Weigh In
Separately, Alliance Global Partners raised shares of Aptose Biosciences to a "strong-buy" rating in a research report on Thursday, February 27th.
View Our Latest Analysis on APS
Aptose Biosciences Trading Down 34.6%
The firm has a market capitalization of C$50.38 million, a P/E ratio of -0.23 and a beta of 1.36. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The stock has a 50 day simple moving average of C$2.60 and a 200-day simple moving average of C$5.62.
About Aptose Biosciences
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aptose Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.
While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
